Moderna's crash proves one day of good trial news is not a verdict

Moderna fell sharply the day after its historic surge, giving back most of Wednesday's gains as investors reassessed Phase III data showing its personalized melanoma vaccine with Merck helped patients stay cancer-free longer.

The reversal is a reminder that a single trial readout, however promising, is not the same as a drug in pharmacies, because full data, regulatory review, and commercial approval all stand between today's headline and real-world impact.

Deere's construction boom shows AI is quietly reshaping heavy equipment demand

Deere beat earnings expectations on Thursday, with its construction and smaller agriculture units picking up the slack from a still-struggling large-farm equipment business, driven by surging demand from data center and energy infrastructure buildouts.

The result is a useful reminder that the AI infrastructure wave reaches far beyond Silicon Valley, now moving dirt, pouring concrete, and lifting Deere's order books.

Alibaba's profit collapse is a deliberate bet that AI spending now beats earnings later

Alibaba reported solid revenue and cloud growth in its latest quarter, but profits fell sharply as the company poured money into AI infrastructure to keep pace with rivals.

With AI now generating more than a third of its cloud revenue, the spending is not waste but the price of staying relevant in a market where falling behind on AI capacity could cost far more than the investment itself.